# Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting

> **NCT02546232** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 196 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02546232
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-04-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546232, "Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02546232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*